Gland Pharma FY26 Annual Earnings Summary

Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.

An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.

Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.

Cenexi's break-even depends on achieving EUR 50 million quarterly revenue; any shortfall could delay profitability.

Partner's U.S. launch delayed due to additional data request; approval expected in February but uncertainty remains.

Management acknowledged quarter-to-quarter fluctuations at Cenexi, which could impact near-term consolidated results.

Despite expanding cartridge capacity, management is conservative on GLP-1 revenue, citing patent and pricing uncertainties.

Saudi Arabia shipments paused due to geopolitical tensions, causing a dip in ROW revenue; recovery uncertain.

Management excludes GLP-1 from guidance due to dependency on partner approvals and market launches, creating upside risk but also uncertainty.

U.S. revenue was flat due to timing of Enoxaparin supplies, a large product. Management expects annual volumes to be intact but quarterly volatility may persist.

Milestone revenue was lower in Q2 (INR 44-45 crore vs. normal INR 75-80 crore) due to timing and U.S. licensing slowdown, impacting quarterly comparisons.

ROW revenue was flat due to a 53% decline in tech transfer/CMO revenue, though product sales grew 19%; recovery may take a few quarters.